Genetic Technological Innovations, LLC

Genetic Technological Innovations, LLC was paid $14.46M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 37% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Arizona

Rank by total paid#5 of 67

Median peer was paid$89K

This provider vs. median162×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	42,188	$659K
2019	43,119	$583K
2020	66,312	$1.16M
2021	69,116	$1.68M
2022	109,031	$2.83M
2023	169,620	$5.59M
2024incomplete	59,593	$1.96M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	37%	98,961	35,503	$5.36M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	13%	19,821	12,027	$1.92M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	6.6%	50,723	17,031	$951K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	6.6%	10,419	7,958	$948K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	5.6%	16,521	12,052	$813K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.6%	26,296	15,614	$659K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.5%	9,317	3,302	$362K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.3%	33,755	16,262	$340K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.7%	6,178	4,520	$246K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.1%	2,760	1,847	$166K
87486		1.1%	8,803	6,528	$155K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	5,644	4,237	$122K

71 more codes

87150		<1%	3,846	$113K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,486	$106K
87640		<1%	11,162	$87K
87496		<1%	11,541	$82K
87532		<1%	11,496	$78K
87581		<1%	8,603	$75K
87541		<1%	8,607	$74K
87500		<1%	11,211	$68K
87634		<1%	5,148	$62K
87481		<1%	8,935	$61K
87653		<1%	11,094	$55K
87641		<1%	10,729	$54K
83992		<1%	3,631	$52K
87498		<1%	5,891	$51K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	10,037	$50K
80349		<1%	3,974	$49K
80354		<1%	3,973	$49K
80358		<1%	3,970	$49K
80348		<1%	3,974	$49K
80372		<1%	3,958	$49K
80373		<1%	3,969	$49K
80365		<1%	3,957	$49K
80357		<1%	3,930	$49K
80371		<1%	3,817	$49K
80345		<1%	3,954	$49K
80346		<1%	4,009	$49K
80324		<1%	3,956	$49K
80323		<1%	3,779	$49K
80361		<1%	3,942	$48K
80360		<1%	3,882	$48K
80368		<1%	3,844	$48K
87631		<1%	1,509	$43K
80353		<1%	3,307	$43K
80359		<1%	3,456	$42K
80350		<1%	3,317	$42K
80356		<1%	3,455	$42K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	2,023	$39K
80375		<1%	2,523	$34K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,462	$32K
87529		<1%	5,389	$28K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	5,161	$25K
87563		<1%	4,960	$23K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	4,830	$21K
G0452	Molecular pathology procedure; physician interpretation and report	<1%	7,315	$18K
82565		<1%	7,943	$18K
87511		<1%	5,042	$16K
87506		<1%	117	$15K
80362		<1%	1,490	$14K
87551		<1%	1,167	$13K
87471		<1%	1,322	$11K
84315		<1%	7,829	$7K
80364		<1%	500	$7K
80370		<1%	496	$7K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	281	$7K
80339		<1%	201	$3K
80338		<1%	293	$3K
80369		<1%	723	$3K
80355		<1%	293	$3K
80342		<1%	181	$3K
80332		<1%	181	$3K
80335		<1%	181	$3K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	975	$2K
87505		<1%	370	$826.73
10005		<1%	20	$500.00
87556		<1%	33	$152.77
87561		<1%	33	$147.39
84311		<1%	422	$63.98
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	26	$35.20
36415	Collection of venous blood by venipuncture	<1%	39	$12.00
80366		0%	112	$0.00
80363		0%	499	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGLIMCHER, NICHOLAS (CEO)